3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Bronchogenic
1
Interventions
pembrolizumab
23
Gemcitabine
9
Nivolumab
7
Carboplatin
7
Trastuzumab
6
Early Intervention, Educational
6
avelumab
5
atezolizumab
5
Docetaxel
5
Cisplatin
5
cemiplimab
4
Standard of Care
4
Psychiatric Rehabilitation
4
Paclitaxel
4
Methods
4
Magnetic Resonance Spectroscopy
4
Ipilimumab
4
Fluorouracil
4
Fluorodeoxyglucose F18
4
Cyclophosphamide
4
Counseling
4
Albumin-Bound Paclitaxel
4
tisotumab vedotin
3
pertuzumab
3
fludarabine
3
Taxes
3
Radiotherapy
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Blood Specimen Collection
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Interleukin-15
×
Gastrointestinal
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled